{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:20:42Z","timestamp":1788247242824,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T00:00:00Z","timestamp":1629331200000},"content-version":"am","delay-in-days":414,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.therap.2020.05.003","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T11:40:28Z","timestamp":1588851628000},"page":"355-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection"],"prefix":"10.1016","volume":"75","author":[{"given":"Jo\u00eblle","family":"Micallef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Soeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie-Pierre","family":"Jonville-B\u00e9ra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7456","key":"10.1016\/j.therap.2020.05.003_bib0325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.therap.2020.05.003_bib0330","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.therap.2018.11.002","article-title":"Pharmacoepidemiology of non-steroidal anti-inflammatory drugs","volume":"74","author":"Moore","year":"2019","journal-title":"Therapies"},{"issue":"7","key":"10.1016\/j.therap.2020.05.003_bib0335","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/00006454-199507000-00007","article-title":"Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients","volume":"14","author":"Brogan","year":"1995","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.therap.2020.05.003_bib0340","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S1047-2797(97)00040-9","article-title":"Ibuprofen and skin and soft tissue superinfections in children with varicella","volume":"7","author":"Choo","year":"1997","journal-title":"Ann Epidemiol"},{"issue":"4","key":"10.1016\/j.therap.2020.05.003_bib0345","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1542\/peds.103.4.783","article-title":"A case-control study of necrotizing fasciitis during primary varicella","volume":"103","author":"Zerr","year":"1999","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.therap.2020.05.003_bib0350","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1542\/peds.107.5.1108","article-title":"Invasive group A streptococcal infection and nonsteroidal anti-inflammatory drug use among children with primary varicella","volume":"107","author":"Lesko","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.therap.2020.05.003_bib0355","series-title":"Point AINS et risque infectieux\u00a0\u2013\u00a0Comit\u00e9 technique de pharmacovigilance\u00a0\u2013\u00a0CT012016043","author":"CRPV de Tours","year":"2016"},{"key":"10.1016\/j.therap.2020.05.003_bib0360","first-page":"5","article-title":"Assessing the relationship between the use of NSAIDs for pain or fever and serious bacterial infection","volume":"31","author":"Jonville-B\u00e9ra","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.05.003_bib0365","series-title":"Rapport d\u2019expertise\u00a0\u2013\u00a0Infections bact\u00e9riennes graves (de la peau et des tissus mous, pleuro-pulmonaires, neurologiques et ORL) rapport\u00e9es avec l\u2019ibuprof\u00e8ne ou le k\u00e9toprof\u00e8ne dans le traitement symptomatique de la fi\u00e8vre ou de douleur non rhumatologique","author":"CRPV de Tours","year":"2019"},{"key":"10.1016\/j.therap.2020.05.003_bib0370","first-page":"30","article-title":"Multi-source comprehensive review on whether ibuprofen exacerbates bacterial infections","author":"Soeiro","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.05.003_bib0375","first-page":"m1185","article-title":"Re: Non-steroidal anti-inflammatory drugs and covid-19","volume":"368","author":"Soeiro","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2020.05.003_bib0380","series-title":"Anti-inflammatoires non st\u00e9ro\u00efdiens (AINS) et complications infectieuses graves\u00a0\u2013\u00a0Point d\u2019information","author":"ANSM","year":"2019"},{"issue":"18","key":"10.1016\/j.therap.2020.05.003_bib0385","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2020.05.003_bib0390","series-title":"J\u2019ai des sympt\u00f4mes, je suis malade COVID-19","author":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","year":"2020"},{"key":"10.1016\/j.therap.2020.05.003_bib0395","doi-asserted-by":"crossref","first-page":"m1086","DOI":"10.1136\/bmj.m1086","article-title":"COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists","volume":"17","author":"Day","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.therap.2020.05.003_bib0400","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.therap.2018.08.001","article-title":"What is pharmacoepidemiology? Definition, methods, interest and clinical applications","volume":"74","author":"Montastruc","year":"2019","journal-title":"Therapies"},{"issue":"4","key":"10.1016\/j.therap.2020.05.003_bib0405","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1086\/338460","article-title":"An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations","volume":"34","author":"Byington","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.therap.2020.05.003_bib0410","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1651-2227.2010.01734.x","article-title":"Prevalence and risk factors of suppurative complications in children with pneumonia: suppurative complications of pneumonia","volume":"99","author":"Fran\u00e7ois","year":"2010","journal-title":"Acta Paediatr"},{"issue":"2","key":"10.1016\/j.therap.2020.05.003_bib0415","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1378\/chest.09-3102","article-title":"Nonsteroidal anti-inflammatory drugs may affect the presentation and course of community-acquired pneumonia","volume":"139","author":"Voiriot","year":"2011","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.therap.2020.05.003_bib0420","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jcrc.2014.05.021","article-title":"Risks of nonsteroidal anti-inflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients","volume":"29","author":"Messika","year":"2014","journal-title":"J Crit Care"},{"issue":"7","key":"10.1016\/j.therap.2020.05.003_bib0425","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ppul.23041","article-title":"Risk factors for the development of pleural empyema in children: risk factors of pediatric empyema","volume":"50","author":"Elemraid","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.therap.2020.05.003_bib0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2016.05.025","article-title":"Nonsteroidal anti-inflammatory drug without antibiotics for acute viral infection increases the empyema risk in children: a matched case-control study","volume":"175","author":"Le Bourgeois","year":"2016","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.therap.2020.05.003_bib0435","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-016-9973-1","article-title":"Non-steroidal anti-inflammatory drugs may worsen the course of community-acquired pneumonia: a cohort study","volume":"195","author":"Basille","year":"2017","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.therap.2020.05.003_bib0440","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/crj.12524","article-title":"Risk factors for local complications in children with community-acquired pneumonia","volume":"12","author":"Krenke","year":"2018","journal-title":"Clin Respir J"},{"issue":"4","key":"10.1016\/j.therap.2020.05.003_bib0445","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.rmr.2017.12.003","article-title":"Risques associ\u00e9s \u00e0 la prise d\u2019anti-inflammatoires non st\u00e9ro\u00efdiens au cours de la pneumonie","volume":"35","author":"Voiriot","year":"2018","journal-title":"Rev Mal Respir"},{"issue":"6","key":"10.1016\/j.therap.2020.05.003_bib0450","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060786","article-title":"Risks related to the use of non-steroidal anti-inflammatory drugs in community-acquired pneumonia in adult and pediatric patients","volume":"8","author":"Voiriot","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.therap.2020.05.003_bib0455","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jpeds.2016.10.058","article-title":"Ibuprofen use in viral infection is associated with subsequent empyema","volume":"180","author":"Little","year":"2017","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.therap.2020.05.003_bib0460","doi-asserted-by":"crossref","first-page":"f6041","DOI":"10.1136\/bmj.f6041","article-title":"Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial","volume":"347","author":"Little","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.therap.2020.05.003_bib0465","doi-asserted-by":"crossref","first-page":"e009769","DOI":"10.1136\/bmjopen-2015-009769","article-title":"Primary care randomised controlled trial of a tailored interactive website for the self-management of respiratory infections (Internet Doctor)","volume":"6","author":"Little","year":"2016","journal-title":"BMJ Open"},{"issue":"7503","key":"10.1016\/j.therap.2020.05.003_bib0470","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.therap.2020.05.003_bib0475","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/BF01709568","article-title":"Prostacyclin counteracts the increase in capillary permeability induced by tumour necrosis factor-\u03b1","volume":"22","author":"Jahr","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.therap.2020.05.003_bib0480","doi-asserted-by":"crossref","first-page":"926968","DOI":"10.1155\/2012\/926968","article-title":"PGI 2 as a regulator of inflammatory diseases","volume":"2012","author":"Dorris","year":"2012","journal-title":"Mediators Inflamm"},{"issue":"8","key":"10.1016\/j.therap.2020.05.003_bib0485","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.4049\/jimmunol.174.8.5033","article-title":"Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury","volume":"174","author":"Fukunaga","year":"2005","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.therap.2020.05.003_bib0490","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/9550","article-title":"Inducible cyclooxygenase may have anti-inflammatory properties","volume":"5","author":"Gilroy","year":"1999","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.therap.2020.05.003_bib0495","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/89759","article-title":"Lipid mediator class switching during acute inflammation: signals in resolution","volume":"2","author":"Levy","year":"2001","journal-title":"Nat Immunol"},{"issue":"14","key":"10.1016\/j.therap.2020.05.003_bib0500","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/0006-2952(84)90661-0","article-title":"In vivo interaction of nonsteroidal anti-inflammatory drugs on the locomotion of neutrophils elicited by acute non-specific inflammations in the rat\u2014Effect of indomethacin, ibuprofen and flurbiprofen","volume":"33","author":"Perianin","year":"1984","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.therap.2020.05.003_bib0505","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/1043-4666(94)90077-9","article-title":"Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock","volume":"6","author":"Pettipher","year":"1994","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.therap.2020.05.003_bib0510","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/clinids\/21.4.977","article-title":"Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome?","volume":"21","author":"Stevens","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.therap.2020.05.003_bib0515","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0022-3565(24)37038-7","article-title":"Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship","volume":"283","author":"Fowler","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.therap.2020.05.003_bib0520","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1476-5381.2008.00029.x","article-title":"The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1","volume":"156","author":"Fowler","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.therap.2020.05.003_bib0525","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nchembio.663","article-title":"(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2","volume":"7","author":"Duggan","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.therap.2020.05.003_bib0530","doi-asserted-by":"crossref","first-page":"978678","DOI":"10.1155\/2014\/978678","article-title":"Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis","volume":"2014","author":"Sardinha","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"4","key":"10.1016\/j.therap.2020.05.003_bib0535","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/metabo7040055","article-title":"Parameters of the endocannabinoid system as novel biomarkers in sepsis and septic shock","volume":"7","author":"Lafreniere","year":"2017","journal-title":"Metabolites"},{"issue":"6","key":"10.1016\/j.therap.2020.05.003_bib0540","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jmii.2011.04.012","article-title":"Ibuprofen worsens Streptococcus pyogenes soft tissue infections in mice","volume":"44","author":"Weng","year":"2011","journal-title":"J Microbiol Immunol Infect"},{"issue":"9","key":"10.1016\/j.therap.2020.05.003_bib0545","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/infdis\/jit594","article-title":"Effects of selective and nonselective nonsteroidal anti-inflammatory drugs on antibiotic efficacy of experimental group A streptococcal myonecrosis","volume":"209","author":"Hamilton","year":"2014","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.therap.2020.05.003_bib0550","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/fcp.12336","article-title":"The role of nonsteroidal anti-inflammatory drugs intramuscular injection in the development and severity of deep soft tissue infection in mice","volume":"32","author":"Ture","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.therap.2020.05.003_bib0555","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/504261","article-title":"Group A streptococcal myonecrosis: increased vimentin expression after skeletal-muscle injury mediates the binding of Streptococcus pyogenes","volume":"193","author":"Bryant","year":"2006","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.therap.2020.05.003_bib0560","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1086\/593016","article-title":"Muscle injury, vimentin expression, and nonsteroidal anti-inflammatory drugs predispose to cryptic group A streptococcal necrotizing infection","volume":"198","author":"Hamilton","year":"2008","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.therap.2020.05.003_bib0565","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/QCO.0000000000000160","article-title":"The roles of injury and nonsteroidal anti-inflammatory drugs in the development and outcomes of severe group A streptococcal soft tissue infections","volume":"28","author":"Bryant","year":"2015","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"10.1016\/j.therap.2020.05.003_bib0570","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000375362","article-title":"Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats","volume":"131","author":"Qiao","year":"2015","journal-title":"Cardiology"},{"issue":"4","key":"10.1016\/j.therap.2020.05.003_bib0575","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med"},{"issue":"6485","key":"10.1016\/j.therap.2020.05.003_bib0580","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"5Yan","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.therap.2020.05.003_bib0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.therap.2020.05.003_bib0590","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbrc.2004.05.114","article-title":"Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin-converting enzyme 2 and infection can be blocked by soluble receptor","volume":"319","author":"Hofmann","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.therap.2020.05.003_bib0595","series-title":"ACE2, IEC\/ARAII et infections \u00e0 COVID-19","author":"SFPT","year":"2020"},{"issue":"5","key":"10.1016\/j.therap.2020.05.003_bib0600","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.therap.2020.05.003_bib0605","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10229","key":"10.1016\/j.therap.2020.05.003_bib0610","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2020.05.003_bib0615","series-title":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9\u00a0\u2013\u00a0Financement en urgence de 11\u00a0projets de recherche appliqu\u00e9e en sant\u00e9 pour pr\u00e8s de 9\u00a0millions d\u2019euros","author":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9","year":"2020"},{"key":"10.1016\/j.therap.2020.05.003_bib0620","series-title":"Efficacy of addition of naproxen in the treatment of critically ill patients hospitalized for COVID-19 infection (ENACOVID)","author":"ClinicalTrials.gov","year":"2020"},{"issue":"5","key":"10.1016\/j.therap.2020.05.003_bib0625","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.therap.2020.05.003_bib0630","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1080\/07391102.2014.979230","article-title":"Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of Influenza A virus","volume":"33","author":"Tarus","year":"2015","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.therap.2020.05.003_bib0635","doi-asserted-by":"crossref","first-page":"m1185","DOI":"10.1136\/bmj.m1185","article-title":"Non-steroidal anti-inflammatory drugs and covid-19","volume":"368","author":"Little","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2020.05.003_bib0640","series-title":"COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community","author":"NICE","year":"2020"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:39Z","timestamp":1758567219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720300925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0040595720300925"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}